Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

NCT02343926 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

443

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: GEMIGLIPTIN LS15-0444
DRUG: vildagliptin
DRUG: metformin

Sponsor

Sanofi